Rita Nanda to United States
This is a "connection" page, showing publications Rita Nanda has written about United States.
Connection Strength
0.176
-
Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States. Breast Cancer Res Treat. 2024 Nov; 208(1):203-214.
Score: 0.086
-
Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA. 2005 Oct 19; 294(15):1925-33.
Score: 0.023
-
Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US. JAMA Netw Open. 2025 02 03; 8(2):e2460243.
Score: 0.022
-
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer. 2021 08; 9(8).
Score: 0.018
-
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol. 2019 01 01; 5(1):74-82.
Score: 0.015
-
Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program. Clin Pharmacol Ther. 2017 07; 102(1):106-114.
Score: 0.013